Zobrazeno 1 - 10
of 108
pro vyhledávání: '"Deborah A. Zarin"'
Publikováno v:
Journal of Clinical and Translational Science, Vol 7 (2023)
Abstract Introduction: Recent revisions to the US Federal Common Rule governing human studies funded or conducted by the federal government require the provision of a “concise and focused” key information (KI) section in informed consent forms (
Externí odkaz:
https://doaj.org/article/09a774c072344be2b9bbd8a3aea42a81
Publikováno v:
eLife, Vol 11 (2022)
Prior studies suggest that clinical trials are often hampered by problems in design, conduct, and reporting that limit their uptake in clinical practice. We have described ‘informativeness’ as the ability of a trial to guide clinical, policy, or
Externí odkaz:
https://doaj.org/article/aef81516fd5b490794914ff3ba2f345e
Publikováno v:
Med. 4:226-232
Autor:
Deborah A, Zarin, Harry P, Selker
Publikováno v:
Clinical Therapeutics. 44:439-441
Autor:
Rebecca J Williams, Heather D Dobbins, Tony Tse, Sandy D Chon, David Loose, Gisele A Sarosy, Sheila A Prindiville, Frank W Rockhold, Deborah A Zarin
Publikováno v:
BMJ (Clinical research ed.). 377
ObjectiveTo describe an approach for reporting master protocol research programs (MPRPs) that is consistent with existing good reporting practices and that uses structured information to convey the overall master protocol and design of each substudy.
Autor:
David L DeMets, Deborah A Zarin, Frank Rockhold, Susan S Ellenberg, Thomas Fleming, Janet Wittes
Publikováno v:
Clinical Trials. :174077452311694
Clinical trials investigating novel or high risk interventions, or studying vulnerable participants, often use a data monitoring committee to oversee the progress of the trial. The data monitoring committee serves both an ethical and a scientific fun
Publikováno v:
JAMA. 329:1404
This study examines the dissemination of trial results by data source (ie, ClinicalTrials.gov and PubMed) and funder type (ie, industry and nonindustry).
BackgroundPrior studies suggest that clinical trials are often hampered by problems in design, conduct and reporting that limit their uptake in clinical practice. We have described “informativeness” as the ability of a trial to guide clinical, po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d912a5819a11a839b1ef4db4d2b46d5
https://doi.org/10.1101/2022.05.12.22275021
https://doi.org/10.1101/2022.05.12.22275021
Autor:
Deborah A Zarin, Tony Tse
Publikováno v:
PLoS Medicine, Vol 13, Iss 1, p e1001946 (2016)
Externí odkaz:
https://doaj.org/article/337e844dc4bb4cf5ac90020e0f12305d
Autor:
Danielle Whicher, Elliott M. Antman, Julie R. Ingelfinger, Joseph S. Ross, Shirley V. Wang, Sameer Siddiqi, Eric D. Peterson, Marianne Hamilton Lopez, Joanne Waldstreicher, Harlan M. Krumholz, Richard Kuntz, Alexander Ommaya, Robert M. Califf, Deborah A. Zarin
Publikováno v:
NAM Perspect